摘要:

9 children presenting with an ampicillin-sensitive coliform urinary tract infection were treated with talampicillin using 1 week of full-dose treatment followed by low-dose prophylaxis. The bowel coliforms were ampicillin-resistant at the start in one girl and became resistant in the remaining 8 within 4 months. During a total of 44 months of talampicillin therapy, 6 girls (2 with vesico-ureteric reflux) developed a symptomatic re-infection of the urinary tract, a recurrence rate of 1 per 7.3 months, or 1.6 recurrences per annum. A further 12 girls were given prophylactic talampicillin, 9 after an initial therapeutic course of co-trimoxazole for 1 week and 3 following a period of prophylaxis with low-dose co-trimoxazole. The rectal swab from one girl showed partial ampicillin resistance but 9 of the remaining 11 showed that a predominance of ampicillin-resistant coliforms had emerged in the bowel flora within 4 months. 5 of the 12 also developed a symptomatic ampicillin-resistant urinary infection within 4 months, a recurrence rate of 1 per 7.1 months or 1.7 recurrences per annum. Talampicillin, though very effective in treating urinary infection, is not recommended for the prevention of subsequent recurrence.

ISSN:0009-3157    

DOI:10.1159/000238080

出版商:S. Karger AG    

年代:1982

数据来源: Karger

摘要:

27 male adult patients with acute soft tissue infections including cellulitis, abscesses, ulcers and wound infections were treated with a dose of 2–4 g/day of cefamandole nafate by the intravenous route for a minimum of 10 days. Most patients were seriously ill with underlying conditions like diabetes mellitus, alcoholism and congestive heart failure and required hospitalization and parenteral antibiotics. Gram-positive cocci (predominantly Staphylococcus aureus) and gram-negative bacilli were recovered on pretreatment cultures from 81% of the patients. Clinical and beacteriologic response was excellent. Disappearance of the signs of infection occurred by the 7th day of treatment, by day 3 of treatment fever was down to normal, and by day 5 of treatment the WBC count was below 8,000. There were very few side effects noted, and there was excellent tolerance to the intravenous drug administration. Cefamandole nafate is a safe, effective and well-tolerated agent in the treatment of skin and soft tissue infections of adult patients caused by susceptible organism

ISSN:0009-3157    

DOI:10.1159/000238081

出版商:S. Karger AG    

年代:1982

数据来源: Karger

摘要:

A parenteral formulation of rifampicin (Rimactan® i.v., Ciba-Geigy, Basel, Switzerland) was administered to 237 critically ill or comatose patients, or patients with gastro-intestinal or absorption problems. There were 160 patients suffering from tuberculosis, 77 suffering from non-tuberculous (non-tb) infections including 30 cases of sepsis, 8 cases of bacterial meningitis and/or cerebral abscess and 9 patients with Legionnaires’ disease. The usual daily dose of rifampicin was 450–600 mg, administered in most cases by i.v. bolus (122 cases) or i.v. drip infusion (79 cases) for a period of 1–113 days. Rifampicin was in all cases combined with one or more antimicrobial drug(s). The physicians considered the therapy as successful when the treatment with oral rifampicin could be instituted soon after parenteral administration or when the patients markedly improved their clinical condition. Of a total of 123 tuberculous patients for whom assessment of efficacy was possible, 100 (81.3%) showed favourable clinical results. Of 40 non-tb patients who could be analysed for clinical progress, 32 (80.0%) had a favourable outcome. Special attention should be drawn to the 11 patients with proven staphylococcal infections, of whom 10 were cured clinically and/or bacteriologically. Thrombophlebitis occurred in 10 out of the 237 (4.2%) patients, almost always in patients who were treated for more than 30 days. Systemic unwanted effects occurred in 14 (5.9%); the relationship to the treatment was not always established. Treatment was withdrawn due to unwanted effects in 5 (2.1%) of the 237 patients. Taking into account the severe, life-threatening infections reported, the results suggest that i.v. rifampicin is useful and in some critically ill patients even life-saving. Tolerability was good, even in long-term i.v. administration, although there seems to be the possibility that thrombophlebitis might develop if treatment is continued over 3

ISSN:0009-3157    

DOI:10.1159/000238082

出版商:S. Karger AG    

年代:1982

数据来源: Karger

ISSN:0009-3157    

DOI:10.1159/000238083

出版商:S. Karger AG    

年代:1982

数据来源: Karger